



## **Therabron Therapeutics Announces Scientific Presentations at the American Thoracic Society (ATS) 2016 International Conference**

**ROCKVILLE, MD, May 11, 2016** — Therabron Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing a new standard in respiratory care, today announced that Aprile Pilon, PhD, Chief Scientific Officer and Founder, will be presenting noteworthy new data regarding clinically relevant scientific findings related to the recombinant human Club Cell 10kDa Protein (rhCC10) drug platform. Two presentations are scheduled at the upcoming American Thoracic Society (ATS) 2016 International Conference, to be held May 13-18, 2016 at the Moscone Center in San Francisco, CA. These presentations will discuss previously unreported observations regarding the use of rhCC10 in a model of traumatic smoke inhalation, as well as effective modifications of rhCC10 by reactive oxygen species, creating a novel anti-inflammatory mechanism.

Details of the presentations are as follows:

**Session Title:** A53 - Respiratory Failure: Risk Factors and Outcomes in ARDS  
**Poster Title:** A1859 - Comparison of rhCC10 Effects in Ovine Model of Traumatic Smoke Inhalation with and Without Dermal Burn (Poster #P557)  
**Date and Time:** Sunday, May 15, 2016, 9:00am - 4:15pm PDT  
**Location:** Area E, Hall D (North Building, Lower Level), Moscone Center

**Session Title:** C73 - Oxidants  
**Poster Title:** A5907 – Modification of CC10 Protein by Reactive Oxygen Species: A Novel Anti-Inflammatory Mechanism (Poster #P924)  
**Date and Time:** Tuesday, May 17, 2016, 11:00am – 12:45pm PDT  
**Location:** Area H, Hall D (North Building, Lower Level), Moscone Center

### **About Therabron Therapeutics, Inc.**

At Therabron Therapeutics, we are advancing a platform of novel therapeutic proteins in an effort to change how a variety of neglected and under-treated respiratory and fibrotic conditions are managed. We are a privately held, clinical-stage biopharmaceutical company, developing a new class of drugs based on the naturally occurring secretoglobin family of proteins, which includes the CC10 protein — a molecule with both anti-inflammatory and immunomodulatory mechanisms. Therabron's product candidates have the potential to become first-in-class biologic therapeutics. For additional information, please visit [www.therabron.com](http://www.therabron.com).

For further information:



**Therabron  
Therapeutics**

Media Relations, Michael Parks, Pitch360: 484.356.7105 or [michael@pitch360inc.com](mailto:michael@pitch360inc.com)  
Investor Relations, Melody Carey, Rx Communications Group LLC: 917.322.2571 or  
[mcarey@rxir.com](mailto:mcarey@rxir.com)

###